Reuters. August 31, 2011. U.S. health regulators said they would consider setting up a registry that tracks safety problems with breast implants, after too many patients dropped out of company-funded studies. NRC president Diana Zuckerman brings up the fact that Allergan has three times more patients participating than the other manufacturer of silicone breast implants Mentor, and that they needed to be held responsible.
Web MD. August 31, 2011. After two days of testimony on what the FDA should do about troubled long-term safety studies of silicone-gel breast implants, agency officials said the studies would continue. Public health research director of the Cancer Prevention and Treatment Fund Dana Casciotti, said the 27 page questionaires that are currently being used in the studies were too long and needed to be shortened and improved if the studies are to be effective.
August 31, 2011. The New York Times. Dr. Diana Zuckerman, president of National Research Center for Women & Families, told an FDA advisory panel that Allergan and Mentor did a poor job studying patients that got silicone implants.
MSNBC. June 22, 2011. Diana Zuckerman, president of the National Research Center for Women & Families, says the studies the FDA used to say silicone implants are safe are incomplete. In addition, Zuckerman claims women need to understand that when they get breast implants they may need removal or replacements for the rest of their lives.
The Miami Herald. July 29, 2011. NRC President Diana Zuckerman expresses concern over the vast majority of medical devices being cleared through the 510(k) process—a process which has been described as “flawed” by Institute of Medicine panelists in a new report.
Washington Post, Letters to the Editor, August 22, 2010. If a breast cancer patient takes Avastin, it will not improve her chances of living longer, but her quality of life is more likely to be harmed because of the debilitating conditions linked to the drug.